Back to Report Store Home

Global Dermatology Drugs Market to 2024 – IL Signaling Inhibitors to Overtake TNF-a Inhibitors as Leading Commercial Drug Class with Dupixent and Cosentyx among Key Performers

  • Published: Dec-2018
  • Report Code: GBIHC486MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Dermatology Drugs Market, 7MM, Epidemiology Patterns for Atopic Dermatitis, 2017–2024 21

Figure 2: Dermatology Drugs Market, 7MM, Epidemiology Patterns for Acne Vulgaris, 2017–2024 22

Figure 3: Dermatology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2017–2024 23

Figure 4: Dermatology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 30

Figure 5: Dermatology Drugs Market, Global, Annual Revenue for Humira ($bn), 2006–2024 32

Figure 6: Dermatology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006–2024 34

Figure 7: Dermatology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006–2024 36

Figure 8: Dermatology Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010–2024 38

Figure 9: Dermatology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015–2024 40

Figure 10: Dermatology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016–2024 41

Figure 11: Dermatology Drugs Market, Global, Annual Revenue for Dupixent ($bn), 2017–2024 43

Figure 12: Dermatology Drugs Market, Global, Annual Revenue for Eucrisa ($bn), 2016–2024 44

Figure 13: Dermatology Drugs Market, Global, Annual Revenue for Neoral ($m), 2006–2024 46

Figure 14: Dermatology Drugs Market, Global, Annual Revenue for Protopic ($m), 2006–2015 47

Figure 15: Dermatology Drugs Market, Global, Annual Revenue for Elidel ($m), 2006–2024 48

Figure 16: Dermatology Drugs Market, Global, Annual Revenue for Differin ($m), 2008–2015 50

Figure 17: Dermatology Drugs Market, Global, Annual Revenue for Elocon ($m), 2006–2024 51

Figure 18: Dermatology Drugs Market, Global, Annual Revenue for Metolate ($m), 2007–2013 52

Figure 19: Dermatology Drugs Market, Global, Annual Revenue for Aczone ($m), 2015–2024 54

Figure 20: Dermatology Drugs Market, Global, Annual Revenue for Retin-A ($m), 2014–2024 56

Figure 21: Dermatology Drugs Market, Global, Annual Revenue for Episalvan ($m), 2020–2024 58

Figure 22: Dermatology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 59

Figure 23: Dermatology Drugs Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2018 61

Figure 24: Dermatology Drugs Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2018 62

Figure 25: Dermatology Drugs Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2018 63

Figure 26: Dermatology Drugs Market, Global, Pipeline for Dermatology by Molecular Target Class, 2018 65

Figure 27: Dermatology Drugs Market, Global, Pipeline for Key Dermatology Indications by Molecular Target Class, 2018 66

Figure 28: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006–2018 67

Figure 29: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006–2018 68

Figure 30: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006–2018 69

Figure 31: Dermatology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target Class and Stage of Development (%), 2006–2018 70

Figure 32: Dermatology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018 70

Figure 33: Dermatology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006–2018 71

Figure 34: Dermatology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2018 72

Figure 35: Dermatology Drugs Market, Global, Clinical Trial Duration by Molecular Target Class and Stage of Development (months), 2006–2018 73

Figure 36: Dermatology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018 73

Figure 37: Dermatology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006–2018 74

Figure 38: Dermatology Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2018 75

Figure 39: Dermatology Drugs Market, Global, Clinical Trial Size by Molecular Target Class and Stage of Development (participants), 2006–2018 76

Figure 40: Dermatology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018 77

Figure 41: Dermatology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006–2018 78

Figure 42: Dermatology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2018 79

Figure 43: Dermatology Drugs Market, Global, Clinical Program Size by Molecular Target Class and Stage of Development (participants), 2006–2018 80

Figure 44: Dermatology Drugs Market, Global, Revenue Forecast for Risankizumab ($bn), 2019–2024 81

Figure 45: Dermatology Drugs Market, Global, Revenue Forecast for MOR106 ($m), 2023–2024 82

Figure 46: Dermatology Drugs Market, Global, Revenue Forecast for ANB-019 ($m), 2020–2024 83

Figure 47: Dermatology Drugs Market, Global, Revenue Forecast for Lebrikizumab ($m), 2021–2024 84

Figure 48: Dermatology Drugs Market, Global, Revenue Forecast for FMX-101 ($m), 2019–2024 85

Figure 49: Dermatology Drugs Market, Global, Market Size ($bn), 2017–2024 86

Figure 50: Dermatology Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024 88

Figure 51: Dermatology Drugs Market, Global, Annual Revenue Forecast for TNF-a inhibitors ($bn), 2017–2024 91

Figure 52: Dermatology Drugs Market, Global, Annual Revenue Forecast for IL-17 inhibitors ($bn), 2017–2024 92

Figure 53: Dermatology Drugs Market, Global, Annual Revenue Forecast for IL-23 inhibitors ($bn), 2017–2024 93

Figure 54: Dermatology Drugs Market, Global, Annual Revenue Forecast for IL-1, 4, 12, 13 and 33 inhibitors ($bn), 2017–2024 94

Figure 55: Dermatology Drugs Market, Global, Annual Revenue Forecast for PDE4 inhibitors ($bn), 2017–2024 95

Figure 56: Dermatology Drugs Market, Global, Annual Revenue Forecast for Glucocorticoids ($bn), 2017–2024 96

Figure 57: Dermatology Drugs Market, Global, Annual Revenue Forecast for JAK inhibitors ($bn), 2019–2024 97

Figure 58: Dermatology Drugs Market, Global, Company Analysis Matrix, 2017–2024 98

Figure 59: Dermatology Drugs Market, Global, Cluster by CAGR and Market Share, 2017–2024 99

Figure 60: Dermatology Drugs Market, Global, Market Share by Company (%), 2017–2024 105

Figure 61: Dermatology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024 107

Figure 62: Dermatology Drugs Market, Global, Revenues by Route of Acquisition, 2017–2024 108

Figure 63: Dermatology Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017–2024 109

Figure 64: Dermatology Drugs Market, Global, Novartis, Annual Revenue Forecast ($bn), 2017–2024 110

Figure 65: Dermatology Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024 111

Figure 66: Dermatology Drugs Market, Global, Sanofi, Annual Revenue Forecast ($bn), 2017–2024 112

Figure 67: Dermatology Drugs Market, Global, Pfizer Annual Revenue Forecast ($bn), 2017–2024 114

Figure 68: Dermatology Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2017–2024 115

Figure 69: Dermatology Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018 116

Figure 70: Dermatology Drugs Market, Global, Overall, High-Activity and Late-Stage Pipeline Developers by Level of Dermatology Specialization, 2018 117

Figure 71: Dermatology Drugs Market, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2017–2024 118

Figure 72: Dermatology Drugs Market, Global, Licensing Deals by Region, Deal Value and Year, 2006–2018 120

Figure 73: Dermatology Drugs Market, Global, Licensing Deals by Key Indication, 2006–2018 121

Figure 74: Dermatology Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018 122

Figure 75: Dermatology Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018 123

Figure 76: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 1) 124

Figure 77: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 2) 125

Figure 78: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 3) 126

Figure 79: Dermatology Drugs Market, Global, Licensing Deals with Disclosed Values, 2006–2018 (part 4) 127

Figure 80: Dermatology Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018 128

Figure 81: Dermatology Drugs Market, Global, Co-development Deals by Indication, 2006–2018 129

Figure 82: Dermatology Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018 129

Figure 83: Dermatology Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018 130

Figure 84: Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 1) 131

Figure 85: Dermatology Drugs Market, Global, Co-development Deals with Disclosed Values, 2006–2018 (part 2) 132

Figure 86: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 1 140

Figure 87: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 2 141

Figure 88: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 3 142

Figure 89: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 4 143

Figure 90: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 5 144

Figure 91: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 6 145

Figure 92: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 7 146

Figure 93: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 8 147

Figure 94: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 9 148

Figure 95: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 10 149

Figure 96: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 11 150

Figure 97: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018 Part 12 151

Figure 98: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 13 152

Figure 99: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 14 153

Figure 100: Dermatology Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018, Part 15 154

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards